Can we rely on contrast-enhanced CT to identify pancreatic ductal adenocarcinoma? A population-based study in sensitivity and factors associated with false negatives.
Max LeBlancJessie KangAndreu F CostaPublished in: European radiology (2023)
• The sensitivities of contrast-enhanced CT for the detection of PDAC were 87/106 (82.1%) and 38/43 (88.4%) for uniphasic and biphasic protocols, respectively. • The sensitivity of contrast-enhanced CT was decreased for small tumors ≤ 2 cm (45.4% vs. 90.6%), if there were no liver metastases (78.0% vs. 95.9%), and with potentially resectable disease (65.3% vs. 93.0%). • Absence of liver metastases (OR, 4.94, 95% CI: 1.29-22.99) and potentially resectable disease (OR, 4.13, 95% CI: 1.07-16.65) were associated with a false--negative (FN) CT result; suspicion of malignancy on the imaging requisition (OR, 0.24, 95% CI: 0.07-0.75) and size > 2 cm (OR, 0.10, 95% CI: 0.02-0.44) were negatively associated with FN.
Keyphrases
- contrast enhanced
- liver metastases
- diffusion weighted
- magnetic resonance imaging
- computed tomography
- magnetic resonance
- dual energy
- diffusion weighted imaging
- high resolution
- image quality
- mass spectrometry
- radiation therapy
- sensitive detection
- rectal cancer
- fluorescence imaging
- real time pcr
- loop mediated isothermal amplification